Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca (typ non-small cell) stadium IB-IIIA po całkowitym usunięciu chirurgicznym
- •Wiek co najmniej 18 lat
- •Dwa badania potwierdzające brak śladów nowotworu we krwi
- •Spodziewana przeżywalność co najmniej 12 tygodni
- •Dobry ogólny stan zdrowia (ECOG 1-2)
- •Zgodę na badania co 3 miesiące przez 2 lata po operacji
✗ Disqualifies
- •Poprzednia chemioterapia, radioterapia lub inne leczenie przeciwnowotworowe
- •Inne nowotwory w ciągu ostatnich 5 lat
- •Ciężkie problemy zdrowotne (aktywna infekcja, wysoki cholesterol, angina, niewydolność serca)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
The First People's Hospital of Foshan
Foshan, China
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, China
Shantou Centeral Hospital
Shantou, China
the First Affiliated Hospital of Shantou University Medical College
Shantou, China
Zhongshan City People's Hospital
Zhongshan, China
Trial contact
Yi-Long Wu, M.D
Xue-Ning Yang, Ph.D
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.